These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29781558)

  • 61. Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.
    Pontillo C; Zhang ZY; Schanstra JP; Jacobs L; Zürbig P; Thijs L; Ramírez-Torres A; Heerspink HJL; Lindhardt M; Klein R; Orchard T; Porta M; Bilous RW; Charturvedi N; Rossing P; Vlahou A; Schepers E; Glorieux G; Mullen W; Delles C; Verhamme P; Vanholder R; Staessen JA; Mischak H; Jankowski J
    Kidney Int Rep; 2017 Nov; 2(6):1066-1075. PubMed ID: 29130072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.
    Pontillo C; Mischak H
    Clin Kidney J; 2017 Apr; 10(2):192-201. PubMed ID: 28694965
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study.
    Joensen LE; Madsen KP; Frimodt-Møller M; Tofte N; Willaing I; Lindhardt M; Rossing P
    J Diabetes Complications; 2020 Jan; 34(1):107467. PubMed ID: 31676252
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease.
    Ghuman JK; Tuttle KR
    Kidney360; 2022 Apr; 3(4):744-748. PubMed ID: 35721619
    [No Abstract]   [Full Text] [Related]  

  • 66. [New breakthrough in type 2 diabetic mellitus with chronic kidney disease: nonsteroidal, highly selective mineralocorticoid receptor antagonist].
    Li H
    Zhonghua Nei Ke Za Zhi; 2021 Jan; 60(1):5-8. PubMed ID: 33397014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention.
    Dubin RF; Rhee EP
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):404-411. PubMed ID: 31636087
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Levels of Urinary Trypsin Inhibitor and Structure of Its Chondroitin Sulphate Moiety in Type 1 and Type 2 Diabetes.
    Lepedda AJ; Nieddu G; Rocchiccioli S; Ucciferri N; Idini M; De Muro P; Formato M
    J Diabetes Res; 2018; 2018():9378515. PubMed ID: 29541644
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options.
    Abdelhafiz AH
    Drugs Aging; 2020 Aug; 37(8):567-584. PubMed ID: 32495289
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kobayashi H; Looker HC; Satake E; Saulnier PJ; Md Dom ZI; O'Neil K; Ihara K; Krolewski B; Galecki AT; Niewczas MA; Wilson JM; Doria A; Duffin KL; Nelson RG; Krolewski AS
    Kidney Int; 2022 Aug; 102(2):370-381. PubMed ID: 35618095
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Study of Protein Biomarkers of Diabetes Mellitus Type 2 and Therapy with Vitamin B1.
    Riaz S
    J Diabetes Res; 2015; 2015():150176. PubMed ID: 26273663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Proteomics and diabetic nephropathy.
    Thongboonkerd V; Barati MT; McLeish KR; Pierce WM; Epstein PN; Klein JB
    Contrib Nephrol; 2004; 141():142-54. PubMed ID: 14650230
    [No Abstract]   [Full Text] [Related]  

  • 73. Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease.
    Rossing P
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1696-1698. PubMed ID: 33239412
    [No Abstract]   [Full Text] [Related]  

  • 74. Proteomics and systems biology for understanding diabetic nephropathy.
    Starkey JM; Tilton RG
    J Cardiovasc Transl Res; 2012 Aug; 5(4):479-90. PubMed ID: 22581264
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Isolating Urinary Extracellular Vesicles as Biomarkers for Diabetic Disease.
    Barreiro K; Huber TB; Holthofer H
    Methods Mol Biol; 2020; 2067():175-188. PubMed ID: 31701453
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of low molecular weight urinary proteins at varying time intervals in type 2 diabetes mellitus and diabetic nephropathy patients.
    Patel DN; Kalia K
    Diabetol Metab Syndr; 2019; 11():39. PubMed ID: 31131043
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biomarkers that predict diabetic nephropathy: the long road from finding targets to clinical use.
    Klein J
    Diabetes; 2012 Dec; 61(12):3072-3. PubMed ID: 23172957
    [No Abstract]   [Full Text] [Related]  

  • 78. Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?
    Tofte N; Persson F; Rossing P
    J Nephrol; 2020 Oct; 33(5):931-948. PubMed ID: 32474762
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A non-laboratory-based risk score for predicting diabetic kidney disease in Chinese patients with type 2 diabetes.
    Wu M; Lu J; Zhang L; Liu F; Chen S; Han Y; Zhao F; Guo K; Bao Y; Chen H; Jia W
    Oncotarget; 2017 Nov; 8(60):102550-102558. PubMed ID: 29254270
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.